Alnylam Pharmaceuticals Inc

ALNY•NASDAQ•HEALTHCARE

$271.77+3.03 (+1.13%)

-6.1% 30D•Market closed•Prev $268.74

-$36.66-11.9%

1 month

-7.6%

price return

Year to date

-32.1%

price return

Recent earnings

4/4

quarters beat

Big funds

8

hold this stock

News tone

Bullish

31 articles, 7 days

Key stats

Jul 26

Market cap: $36.28B
P/E: 67.6x
Forward P/E: 30.0x
Beta: 0.27
Volume: 1.15M
52-week range: $262.21 - $495.55

Analysts

What do analysts expect?

Current

$271.77

Target

$432.04

+160.27 (+59.0%) possible upside12 months

Fundamentals

Business quality, value, and expectations at a glance.

Fundamentals

Is the business strong?

Richly priced and profitable.

Revenue (TTM): $4.3B
Net income (TTM): $577M
Net margin: 12.6%
P/E: 67.60
Forward P/E: 30.03
Market cap: $36.3B

Valuation

P/S8.46
P/B33.74

Quality

Operating margin23.0%
ROE90.4%
ROA10.1%

Growth

Beta0.27

Earnings

Recent earnings versus expectations

Last 8 quarters

QuarterEPS resultNext day

Q1 '26beat +35.3%-4.3%

Q4 '25beat +0.8%+1.9%

Q3 '25beat +101.4%+1.4%

Q2 '25beat +27.1%+2.4%

Q1 '25beat +97.3%Not available

Q4 '24beat +142.9%Not available

Smart money

Filed positions and reported activity tied to this stock.

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$13.1B

BG
Baillie Gifford & Co
Q1 2026 13F
$825.1M
position
TS
Two Sigma
Q1 2026 13F
$659.3M
position
D&
Dodge & Cox
Q1 2026 13F
$638.3M
position
MW
Marshall Wace
Q1 2026 13F
$363.7M
position
DS
D.E. Shaw
Q1 2026 13F
$350.4M
position

Show all 8 holders

FL
FMR LLC
Q1 2026 13F
$4.8B
position
B
BlackRock
Q1 2026 13F
$3.5B
position
JC

Insiders

What insiders are doing

2 trades · 6 mo

Sold$2.4M

Sells (2)

PD
Pyott David E I
Dir · Jun 3
$1.1M
sold
MM
Mclaughlin Melissa
Chief Human Resources Officer · Apr 7
$1.3M
sold

Checking federal contract awards

Coverage gaps for ALNYNo recent market-voice mention

Technicals

Trend, range, and the price levels that matter.

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

27oversold

20D volatility

40%annualized

52-week range

$271.77

$262.21$495.55

20D support

$262.21recent floor

20D resistance

$380.00recent ceiling

Returns

5D +1.6%20D -7.3%60D -10.0%

Price vs moving averages

SMA20 -6.6%SMA50 -6.9%SMA200 -23.3%

Volume pace

1.21xvs prior 20D

News

Recent coverage and its overall tone.

News

What the news says

31 articles · 7 days

Coverage leans bullish

15 bullish · 10 neutral · 6 bearish

Tone of tracked coverage

ALNY Stock Price Today - Alnylam Pharmaceuticals Inc News, Charts, Retail Sentiment
Leans bullishJul 24
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history
Leans bullishJul 24
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Leans bullishJul 23
US2043QAC1 Bond Risk Profile
NeutralJul 23
Alnylam Pharmaceuticals Price Target Cut to $400.00/Share From $420.00 by JP Morgan
Leans bearishJul 23
US2043QAC1 Bond Profile — Key Metrics
NeutralJul 22
Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary
BullishJul 21
Alnylam Stock And 2 US Health Care Names With Earnings In Focus
NeutralJul 20

Q3 '24miss -28.2%Not available

Q2 '24beat +88.0%Not available

Q1 '26beat +35.3%

$1.99 actualNext day -4.3%

Q4 '25beat +0.8%

$1.25 actualNext day +1.9%

Q3 '25beat +101.4%

$2.90 actualNext day +1.4%

Q2 '25beat +27.1%

-$0.51 actualNext day +2.4%

Q1 '25beat +97.3%

-$0.01 actualNext day not available

Q4 '24beat +142.9%

$0.06 actualNext day not available

Q3 '24miss -28.2%

-$0.50 actualNext day not available

Q2 '24beat +88.0%

-$0.13 actualNext day not available

JPMorgan Chase

Q1 2026 13F

$2.0B

position